The Irradiation Facility at Fox Chase Cancer Center (FCCC) manages the shared use of
ionizing radiation sources according to procedures mandated in our license from the Nuclear
Regulatory Commission (NRC). Management and maintenance of these potentially dangerous,
costly devices ($100,000-$200,000 each) as a shared resource for multiple users facilitates
administration, quality assurance, safety and regulatory compliance. The Facility consists of two
different irradiators, each sited optimally for its specific use. They produce fields of Cesium-137
gamma-rays to irradiate molecules in solution, cell cultures, rodent tumors or normal tissues for
studies of radiobiologic mechanisms, to suppress immune response, to induce DMA damage and/or mitotic arrest, and to sterilize cell and drug preparations. The Shepherd Model 280 irradiator is situated in the Laboratory Animal Facility and used mainly for whole body irradiation of animals used in immunobiology research (see Hayakawa et al., J. Exp. Med. 197:87-99, 2003; Allman et al., J. Immunol. 167:6834-6840, 2001). The panoramic Shepherd Model 81-14R irradiator is situated in the basement of the Reimann Building. It was used 223 times in 2003 primarily for the irradiation of cells (see, for example, Katz et al., J. Virol. 76:5422-5434, 2002; Mu et al., Int. J. Radiat. Oncol. Biol. Phys. 58:336-343, 2004). Oversight of Facility operation is provided by the Facility Manager, Facility Director, Radiation Safety Officer, Radiation Safety Committee, FCCC Administration and the NRC. Facility staff operate various radiation dosimeters to accurately determine the dose to experimental set-ups and is available to FCCC investigators for planning radiation experiments, to assist infrequent users, for training individuals to become qualified irradiator users in accord with NRC and other safety regulations and for overseeing the annual maintenance and quality assurance of equipment. Inventories of the radioactive sources are made at intervals determined by the Homeland Security threat level. Over the last Core grant cycle, the Facility was used by 24 peer-reviewed funded investigators from ten FCCC research Programs in two Center Divisions. Currently, 92% of Facility use is by peer-reviewed funded investigators. Facility use has increased about 10% per year and is projected to increase 5-10% per year during the next Core grant cycle.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
biomedical facilityionizing radiationneoplasm /cancerwhole body irradiation dosage
No Sub Projects information available for 5P30CA006927-44 9032
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P30CA006927-44 9032
Patents
No Patents information available for 5P30CA006927-44 9032
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P30CA006927-44 9032
Clinical Studies
No Clinical Studies information available for 5P30CA006927-44 9032
News and More
Related News Releases
No news release information available for 5P30CA006927-44 9032
History
No Historical information available for 5P30CA006927-44 9032
Similar Projects
No Similar Projects information available for 5P30CA006927-44 9032